At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Apr 27, 2026 at 07:00 ET
Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per share), slightly narrower than the consensus estimate of a $0.30 loss. The company highlighted positive clinical data for pociredir in sickle cell disease, plans to initiate a registration-enabling trial in H2 2026, and ended the quarter with $333.3M in cash, providing runway into 2029. CFO Alan Musso announced retirement later this year.
- Q1 2026 net loss of $18.9M ($0.25 per share) vs consensus estimate of $0.30 loss per share
- Cash, cash equivalents and marketable securities of $333.3M as of March 31, 2026, down from $352.3M at year-end 2025
- Positive clinical data from Phase 1b PIONEER trial of pociredir in sickle cell disease presented in Q1 2026
- Plans to initiate a potential registration-enabling trial for pociredir in H2 2026 pending FDA feedback
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access